Adamis Pharmaceuticals Corporation

Description

• Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. Its specialty pharmaceutical division currently has four products in its pipeline including the Epinephrine Injection Pre-filled Syringe (PFS) for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 (Dry Powder Inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (COPD), and APC-3000, a hydrofluoroalkane (HFA) inhaled nasal steroid product for the treatment of allergic rhinitis. This divisions focus is to create low cost therapeutic alternatives to existing treatments in large markets. Adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. Within its biotechnology division, the Company has four products under development include TeloB-VAX, a novel cell-based therapeutic cancer vaccine for prostate cancer and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.
• 

  Headquarters:11682 El Camino Real Suite 300, San Diego, California, United States

  More
• 

  Phone Number: +1 858-997-2400

• 

  Website: https://www.adamispharmaceuticals.com

• 

  Employees:20

• 

  Revenue:$1 - 10M

• 

  Legal Name:Adamis Pharmaceuticals Corporation

• Adamis Pharmaceuticals Corporation's Social Media

  
• Is this data correct?

• |  NAICS Code: 541715  |

  Show More